<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id><journal-title-group><journal-title>Intensive Care Medicine</journal-title></journal-title-group><issn pub-type="ppub">0342-4642</issn><issn pub-type="epub">1432-1238</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21380525</article-id><article-id pub-id-type="pmc">3058361</article-id><article-id pub-id-type="publisher-id">2144</article-id><article-id pub-id-type="doi">10.1007/s00134-011-2144-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Experimental</subject></subj-group></article-categories><title-group><article-title>The effects of levosimendan and glibenclamide on circulatory and metabolic variables in a canine model of acute hypoxia</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Schwarte</surname><given-names>Lothar A.</given-names></name><address><email>L.Schwarte@vumc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schwartges</surname><given-names>Ingo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schober</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Picker</surname><given-names>Olaf</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Anaesthesiology, VU University Medical Center, Amsterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Anaesthesiology, University Hospital Duesseldorf, Duesseldorf, Germany </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>3</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2011</year></pub-date><volume>37</volume><issue>4</issue><fpage>701</fpage><lpage>710</lpage><history><date date-type="received"><day>10</day><month>8</month><year>2010</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2011</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2011</copyright-statement></permissions><abstract id="Abs1"><sec><title>Purpose</title><p>To study the effects of pretreatment with levosimendan (LEVO, a Ca<sup>2+</sup>-sensitizer and K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel opener) and/or the K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel antagonist glibenclamide (GLIB) on systemic hemodynamics, metabolism, and regional gastromucosal oxygenation during hypoxic hypoxemia.</p></sec><sec><title>Methods</title><p>Chronically instrumented, healthy dogs (24&#x02013;32&#x000a0;kg, <italic>n</italic>&#x000a0;=&#x000a0;6 per group, randomized cross-over design) were repeatedly sedated, mechanically ventilated (FiO<sub>2</sub>&#x000a0;~0.3) and subjected to the following interventions: no pretreatment, LEVO pretreatment, GLIB pretreatment, or combined LEVO&#x000a0;+&#x000a0;GLIB pretreatment, each followed by hypoxic hypoxemia (FiO<sub>2</sub>&#x000a0;~0.1). We measured cardiac output (CO, ultrasonic flow probes), oxygen consumption (VO<sub>2</sub>, indirect calorimetry), and gastromucosal microvascular hemoglobin oxygenation (&#x003bc;HbO<sub>2</sub>, spectrophotometry). Statistics: data are presented as mean&#x000a0;&#x000b1;&#x000a0;SEM and compared by one-way ANOVA (direct drug effects within group) and two-way ANOVA (between all hypoxic conditions) both with Bonferroni corrections; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec><sec><title>Results</title><p>In LEVO-pretreated hypoxemia, CO was significantly higher compared to unpretreated hypoxemia. The increased CO was neither associated with an increased VO<sub>2</sub> nor with markers of aggravated anaerobiosis (pH, BE, lactate). In addition, LEVO pretreatment did not further compromise gastromucosal &#x003bc;HbO<sub>2</sub> in hypoxemia. After combined LEVO&#x000a0;+&#x000a0;GLIB pretreatment, systemic effects of GLIB were apparent, however, CO was significantly higher than during unpretreated and GLIB-pretreated hypoxemia, but equal to LEVO-pretreated hypoxemia, indicating that GLIB did not prevent the increased CO in LEVO-pretreated hypoxia.</p></sec><sec><title>Conclusions</title><p>LEVO pretreatment resulted in improved systemic circulation (CO) during hypoxemia without fueling systemic VO<sub>2</sub>, without aggravating systemic anaerobiosis markers, and without further compromising microvascular gastromucosal oxygenation. Thus, LEVO pretreatment may be an option to support the systemic circulation during hypoxia.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Levosimendan</kwd><kwd>Hypoxia</kwd><kwd>Glibenclamide</kwd><kwd>Microcirculation</kwd><kwd>Oxygen</kwd><kwd>Metabolism</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Copyright jointly held by Springer and ESICM 2011</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>Hypoxemia complicates critical care settings, ranging from progressed lung disease to certain medical interventions [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Clearly, reversing hypoxemia is pivotal [<xref ref-type="bibr" rid="CR4">4</xref>], but adapting pharmacological interventions to support the subject during impending or actual hypoxemia also appears beneficial. Systemic hypoxemia triggers multiple patho-mechanisms [<xref ref-type="bibr" rid="CR5">5</xref>] also affecting the cardiovascular system: among others, at the cardiac level hypoxia depresses cardiac function by myofilament Ca<sup>2+</sup>-desensitization [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], and at the vascular level hypoxia triggers activation of K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels [<xref ref-type="bibr" rid="CR8">8</xref>], facilitating blood flow to tissues otherwise at risk for hypoperfusion by intense vasoconstriction.</p><p>In this context, the inodilator levosimendan (LEVO) appears to be an attractive option to support the cardiovascular system at risk in (impending) hypoxemia since it acts both as cardiac myofilament Ca<sup>2+</sup>-sensitizer and K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel opener, thus reversing hypoxia-induced cardiodepression and supporting regional vasodilation. This appears to be particularly of interest in hypoxic settings, since LEVO putatively increases cardiac output (CO) partly independent of an additional increase in oxygen consumption (VO<sub>2</sub>) [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Hypoxia, like other cardiovascular stressors, triggers impairment of splanchnic oxygenation, likely through a combination of abnormal mesenteric perfusion [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>] and hypoxemia. However, particularly the gastrointestinal mucosa is susceptible to hypoxia, and mucosal hypoxia appears to trigger the development of critical illness [<xref ref-type="bibr" rid="CR13">13</xref>]. Thus, interventions intended to improve systemic (hemodynamic) variables during hypoxia should not further compromise regional mucosal circulation or oxygenation [<xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, in addition to systemic variables, we measured the effects on regional gastromucosal oxygenation.</p><p>Clinically, LEVO is primarily indicated for the treatment of acute and chronic ischemic cardiac failure, with promising clinical data available [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Moreover, LEVO is also increasingly advocated to treat nonischemic cardiac failure, including septic or toxic cardiodepression [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. The beneficial effects of LEVO, in addition to positive inotropic effects, may be caused by vasodilation [<xref ref-type="bibr" rid="CR24">24</xref>]. Mechanistically, vasodilation by LEVO is mediated by activation of K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels, which also appear involved in the vasodilation triggered by hypoxia [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p>These K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels, activated by LEVO or hypoxia, are pharmacologically blocked by glibenclamide (GLIB) [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. In this context, GLIB pretreatment has previously been published as a research tool to study the contribution of GLIB-sensitive K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels to the effects of LEVO and other cardiovascular challenges [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Thus, to elucidate the contribution of K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels in the present study, we tested if K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel blockade by GLIB pretreatment would alter the (circulatory) condition during hypoxia, both with and without a LEVO pretreatment.</p><p>GLIB, based on the same mechanism, i.e., antagonizing K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel-dependent vasodilation, is of growing interest in intensive care medicine [<xref ref-type="bibr" rid="CR31">31</xref>]. In this context, GLIB is studied as nonadrenergic vasopressor in various shock-related vasodilatory states, caused by excessive K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel activation. Examples for this therapeutic concept are septic or hemorrhagic vasodilation [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. In this regard, GLIB increases systemic vascular resistance and thus arterial blood pressure [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>In the present study, the combination of LEVO (to increase cardiac contractility) and GLIB (to increase systemic vascular resistance) could achieve the putatively beneficial combination of antagonizing both possible cardiodepressant and vasodilatory effects of systemic hypoxia.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><p>The data derive from repetitive experiments on healthy dogs (foxhounds, <italic>n</italic>&#x000a0;=&#x000a0;6, 24&#x02013;32&#x000a0;kg) treated in accordance with the National Institutes of Health guidelines for animal care and with approval of the District Governmental Animal Investigation Committee.</p><p>For the continuous measurement of cardiac output (CO), ultrasonic flow transducers (S-series, Transonic, Ithaca, NY, USA) were chronically implanted around the pulmonary artery [<xref ref-type="bibr" rid="CR34">34</xref>]. Before the experiments, food was withheld for 12&#x000a0;h. The experiments were performed under sedation with sevoflurane (end-tidal concentration 3.0 vol%, corresponding to ~1.25 MAC in dogs [<xref ref-type="bibr" rid="CR35">35</xref>]) and neuromuscular block (rocuronium 0.6&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup>, followed by 1.0&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;h<sup>&#x02212;1</sup>). Mechanical ventilation (FiO<sub>2</sub> 0.3; tidal volume 12.5&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup> in dogs [<xref ref-type="bibr" rid="CR36">36</xref>], respiratory rate ~20&#x000a0;min<sup>&#x02212;1</sup>) was adjusted to maintain normocapnia as verified by continuous capnography (end-tidal CO<sub>2</sub> 35&#x000a0;torr) and arterial blood gas analysis. The dogs were covered with warming blankets to maintain body temperature (~37.5&#x000b0;C, rectal thermoprobe).</p><sec id="Sec3"><title>Measurements</title><sec id="Sec4"><title>Systemic oxygen consumption</title><p>Systemic oxygen consumption (VO<sub>2</sub>) was measured continuously by indirect calorimetry (Deltatrac-II metabolic monitor, Datex, Helsinki, Finland) and thus was methodologically independent from the determination of CO and DO<sub>2</sub> [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec5"><title>Systemic hemodynamics and oxygenation</title><p>We continuously measured heart rate (HR, electrocardiogram), mean arterial (aortic) pressure (MAP; P23ID, Elk Grove, CA, USA), central venous pressure (P23ID; right atrial catheter tip position confirmed by fluoroscopy), and ultrasound-derived CO (flowmeter T106, Transonic). At the end of each intervention, we performed transpulmonary thermodilution (PiCCO monitor with thermistor-tipped carotid catheter PV-2014L, Pulsion, Munich, Germany; measurements performed according to the manufacturer; with ~0.4&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup> iced saline) to determine the following: global end diastolic volume (GEDV), derived intrathoracic blood volume (ITBV), and extravascular lung water (EVLW). The PiCCO system also provided the pulse-contour-derived stroke volume variation (SVV) and the estimate of cardiac contractility +d<italic>P</italic>/d<italic>t</italic><sub>max</sub>. This system is validated to measure EVLW in dogs [<xref ref-type="bibr" rid="CR37">37</xref>] and has also been applied in other canine studies [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p>Intermittently we measured arterial blood gas tensions (PaO<sub>2</sub>, PaCO<sub>2</sub>) and acid/base-related variables [pH, base excess (BE); ABL-700, Radiometer, Copenhagen, Denmark; no buffer solutions were used]. Additionally, we determined arterial serum metabolites (glucose, lactate) and electrolytes ([K<sup>+</sup>], [Ca<sup>2+</sup>], [Na<sup>+</sup>], [Cl<sup>&#x02212;</sup>]). According to standard formulas, we calculated systemic vascular resistance (SVR), arterial oxygen content (CaO<sub>2</sub>), and systemic oxygen transport (DO<sub>2</sub>).</p></sec><sec id="Sec6"><title>Gastromucosal oxygenation</title><p>Gastromucosal oxygenation was continuously assessed by reflectance spectrophotometry [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Briefly, light (502&#x02013;628&#x000a0;nm) is transmitted to the tissue via a micro light guide, and the reflected light is analyzed for the percentage of oxygenated microvascular hemoglobin (&#x003bc;HbO<sub>2</sub>). The flexible probe (diameter 2.0&#x000a0;mm) was introduced into the stomach via an orogastric silicone tube (14 Charri&#x000e8;re). During the experiments, correct probe position was confirmed by online evaluation of the signal quality (software version 2.0).</p></sec></sec><sec id="Sec7"><title>Experimental program</title><p>After induction (propofol 4&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup> i.v.) and endotracheal intubation, all catheters were inserted and 30&#x000a0;min was allowed to establish steady-state conditions. Blood was sampled for baseline analysis, and thereafter a randomization was performed to allocate the dogs to the experimental groups.</p></sec><sec id="Sec8"><title>Hypoxia episodes</title><p>The hypoxic episodes were induced by switching FiO<sub>2</sub> from 0.30 to 0.11 [<xref ref-type="bibr" rid="CR40">40</xref>], as continuously measured (Capnomac ultima, Datex Instrumentarium, Helsinki, Finland). Each hypoxic episode was maintained for 15&#x000a0;min to allow steady states of the measured variables to be achieved.</p></sec><sec id="Sec9"><title>Drugs</title><p>The agents LEVO and GLIB were infused as follows by a pressure-limited infusion pump via the central venous catheter.</p><sec id="Sec10"><title>LEVO</title><p>After baseline measurements, LEVO (Simdax, Abbott, Wiesbaden, Germany) was administered with an initial loading dose of 20.0&#x000a0;&#x003bc;g&#x000a0;kg<sup>&#x02212;1</sup> over 15&#x000a0;min, followed by continuous infusion of 0.25&#x000a0;&#x003bc;g&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> for the remaining experimental period, a dosing regimen adapted from a similar canine model [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec><sec id="Sec11"><title>GLIB</title><p>GLIB (G0639, Sigma, Frankfurt, Germany), as K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel antagonist, was infused at a dose of 0.2&#x000a0;mg&#x000a0;kg<sup>&#x02212;1</sup> over 10&#x000a0;min, and 30&#x000a0;min were allowed for stabilization. This dose was derived from previous canine studies addressing the contribution of K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels to the effects of LEVO and other cardiovascular modulators [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec></sec><sec id="Sec12"><title>Experimental protocols</title><sec id="Sec13"><title>Group I</title><p>This protocol served to study the effects of hypoxia per se and to study the associated effects of GLIB pretreatment. After steady-state baseline measurements, a first hypoxic challenge was performed. After 60&#x000a0;min recovery from this hypoxia (measurements after 30 and 60&#x000a0;min recovery), GLIB was infused. Following this GLIB pretreatment, a second hypoxic episode was induced.</p></sec><sec id="Sec14"><title>Group II</title><p>This protocol served to study the effects of LEVO pretreatment on hypoxia and further to study the role of GLIB pretreatment in this regard. After a baseline period, LEVO pretreatment was administered, and thereafter a first hypoxic episode was induced. After 60&#x000a0;min recovery from this hypoxia (measurements after 30 and 60&#x000a0;min recovery), with LEVO continuously infused, GLIB pretreatment was administered. Thereafter, with the combined LEVO&#x000a0;+&#x000a0;GLIB pretreatment, a second hypoxic challenge was induced.</p></sec></sec><sec id="Sec15"><title>Statistical analysis</title><p>Statistical analysis was performed using Prism software (version 5.0, GraphPad, La Jolla, CA, USA). Data are presented as absolute values of mean&#x000a0;&#x000b1;&#x000a0;SEM for <italic>n</italic>&#x000a0;=&#x000a0;6 animals per group in the manuscript and tables. Direct drug effects (before onset of hypoxemia) were described by one-way ANOVA for repeated measurements, corrected for multiple comparisons (Bonferroni). Differences during hypoxemia were tested both between groups (i.e., I and II) and between the hypoxia conditions (i.e., without and with GLIB pretreatment) using a two-way ANOVA, corrected for multiple comparisons (Bonferroni). Significance was assumed at <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.

</p></sec></sec><sec id="Sec16"><title>Results</title><sec id="Sec17"><title>Hypoxia model</title><p>Hypoxia was induced by reducing FiO<sub>2</sub> from 0.3 to 0.11, with maintenance of end-tidal CO<sub>2</sub> (35&#x000a0;torr) and end-tidal sevoflurane (3.0 vol%) concentrations. This was achieved for all four hypoxic conditions without significant inter- or intragroup differences (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Hypoxia model</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Condition</th><th align="left">Baseline</th><th align="left">LEVO</th><th align="left">Hypoxia-1</th><th align="left">Recovery-30</th><th align="left">Recovery-60</th><th align="left">GLIB</th><th align="left">Hypoxia-2</th><th align="left">Recovery-30</th></tr></thead><tbody><tr><td align="left" rowspan="2">FiO<sub>2</sub> (%)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;0.0</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">10.9&#x000a0;&#x000b1;&#x000a0;0.1<sup>a</sup></td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;0.0</td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;0.0</td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;0.0</td><td char="&#x000b1;" align="char">11.3&#x000a0;&#x000b1;&#x000a0;0.1<sup>a</sup></td><td char="&#x000b1;" align="char">29.1&#x000a0;&#x000b1;&#x000a0;0.0</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">29.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">29.1&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="&#x000b1;" align="char">10.6&#x000a0;&#x000b1;&#x000a0;0.3<sup>a</sup></td><td char="&#x000b1;" align="char">29.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">29.2&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">10.7&#x000a0;&#x000b1;&#x000a0;0.3<sup>a</sup></td><td char="&#x000b1;" align="char">29.0&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td align="left" rowspan="2">CaO<sub>2</sub> (mL&#x000a0;dL<sup>&#x02212;1</sup>)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">17.3&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">11.7&#x000a0;&#x000b1;&#x000a0;0.6<sup>a</sup></td><td char="&#x000b1;" align="char">16.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="&#x000b1;" align="char">16.4&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="&#x000b1;" align="char">16.6&#x000a0;&#x000b1;&#x000a0;1.0</td><td char="&#x000b1;" align="char">11.1&#x000a0;&#x000b1;&#x000a0;0.5<sup>a</sup></td><td char="&#x000b1;" align="char">16.9&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">17.1&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">16.9&#x000a0;&#x000b1;&#x000a0;0.5*</td><td char="&#x000b1;" align="char">10.3&#x000a0;&#x000b1;&#x000a0;0.8<sup>a</sup></td><td char="&#x000b1;" align="char">16.7&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">16.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">16.8&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">9.4&#x000a0;&#x000b1;&#x000a0;0.7<sup>a</sup></td><td char="&#x000b1;" align="char">17.1&#x000a0;&#x000b1;&#x000a0;0.7</td></tr><tr><td align="left" rowspan="2">PaO<sub>2</sub> (torr)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">133&#x000a0;&#x000b1;&#x000a0;9</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">39&#x000a0;&#x000b1;&#x000a0;1<sup>b,c</sup></td><td char="&#x000b1;" align="char">133&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">137&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">135&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">36&#x000a0;&#x000b1;&#x000a0;1<sup>b</sup></td><td char="&#x000b1;" align="char">128&#x000a0;&#x000b1;&#x000a0;8</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">136&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">135&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">34&#x000a0;&#x000b1;&#x000a0;1<sup>b,c</sup></td><td char="&#x000b1;" align="char">129&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">136&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">134&#x000a0;&#x000b1;&#x000a0;8</td><td char="&#x000b1;" align="char">32&#x000a0;&#x000b1;&#x000a0;2<sup>b</sup></td><td char="&#x000b1;" align="char">125&#x000a0;&#x000b1;&#x000a0;9</td></tr><tr><td align="left" rowspan="2">SaO<sub>2</sub> (%)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">68&#x000a0;&#x000b1;&#x000a0;1<sup>b</sup></td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">64&#x000a0;&#x000b1;&#x000a0;2<sup>b</sup></td><td char="&#x000b1;" align="char">97&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">60&#x000a0;&#x000b1;&#x000a0;3<sup>b</sup></td><td char="&#x000b1;" align="char">97&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;0<sup>$</sup></td><td char="&#x000b1;" align="char">54&#x000a0;&#x000b1;&#x000a0;4<sup>b</sup></td><td char="&#x000b1;" align="char">97&#x000a0;&#x000b1;&#x000a0;0</td></tr><tr><td align="left" rowspan="2">PaCO<sub>2</sub> (torr)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">35&#x000a0;&#x000b1;&#x000a0;1<sup>a</sup></td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">37&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">36&#x000a0;&#x000b1;&#x000a0;1<sup>a</sup></td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">37&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1*</td><td char="&#x000b1;" align="char">37&#x000a0;&#x000b1;&#x000a0;1<sup>a</sup></td><td char="&#x000b1;" align="char">39&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">37&#x000a0;&#x000b1;&#x000a0;1<sup>a</sup></td><td char="&#x000b1;" align="char">38&#x000a0;&#x000b1;&#x000a0;1</td></tr><tr><td align="left" rowspan="2">pH</td><td align="left">Group I</td><td char="&#x000b1;" align="char">7.35&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">7.37&#x000a0;&#x000b1;&#x000a0;0.01<sup>a</sup></td><td char="&#x000b1;" align="char">7.34&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.36&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.36&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.38&#x000a0;&#x000b1;&#x000a0;0.01<sup>a</sup></td><td char="&#x000b1;" align="char">7.35&#x000a0;&#x000b1;&#x000a0;0.01</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">7.36&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.36&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.37&#x000a0;&#x000b1;&#x000a0;0.01<sup>a</sup></td><td char="&#x000b1;" align="char">7.34&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.35&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.35&#x000a0;&#x000b1;&#x000a0;0.01</td><td char="&#x000b1;" align="char">7.36&#x000a0;&#x000b1;&#x000a0;0.01<sup>a</sup></td><td char="&#x000b1;" align="char">7.33&#x000a0;&#x000b1;&#x000a0;0.01</td></tr><tr><td align="left" rowspan="2">HCO<sub>3</sub><sup>&#x02212;</sup> (mmol&#x000a0;L<sup>&#x02212;1</sup>)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">20.2&#x000a0;&#x000b1;&#x000a0;0.6</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">19.8&#x000a0;&#x000b1;&#x000a0;0.5<sup>a</sup></td><td char="&#x000b1;" align="char">20.0&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">20.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">20.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">20.6&#x000a0;&#x000b1;&#x000a0;0.5<sup>a</sup></td><td char="&#x000b1;" align="char">20.5&#x000a0;&#x000b1;&#x000a0;0.6</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">20.3&#x000a0;&#x000b1;&#x000a0;0.4</td><td char="&#x000b1;" align="char">20.8&#x000a0;&#x000b1;&#x000a0;0.3</td><td char="&#x000b1;" align="char">20.6&#x000a0;&#x000b1;&#x000a0;0.3<sup>a</sup></td><td char="&#x000b1;" align="char">20.5&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">20.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">20.6&#x000a0;&#x000b1;&#x000a0;0.5</td><td char="&#x000b1;" align="char">20.2&#x000a0;&#x000b1;&#x000a0;0.4<sup>a</sup></td><td char="&#x000b1;" align="char">19.6&#x000a0;&#x000b1;&#x000a0;0.5</td></tr><tr><td align="left" rowspan="2">Lactate (mmol&#x000a0;L<sup>&#x02212;1</sup>)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">2.3&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">2.6&#x000a0;&#x000b1;&#x000a0;0.0<sup>b</sup></td><td char="&#x000b1;" align="char">2.5&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">2.2&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.1<sup>$</sup></td><td char="&#x000b1;" align="char">1.2&#x000a0;&#x000b1;&#x000a0;0.1<sup>b</sup></td><td char="&#x000b1;" align="char">0.9&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">1.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">2.0&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">2.3&#x000a0;&#x000b1;&#x000a0;0.1<sup>b</sup></td><td char="&#x000b1;" align="char">2.1&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">2.0&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">1.1&#x000a0;&#x000b1;&#x000a0;0.1<sup>$</sup></td><td char="&#x000b1;" align="char">1.1&#x000a0;&#x000b1;&#x000a0;0.1<sup>b</sup></td><td char="&#x000b1;" align="char">0.8&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td align="left" rowspan="2">Glucose (mg&#x000a0;dL<sup>&#x02212;1</sup>)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">100&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">(n.d.)</td><td char="&#x000b1;" align="char">106&#x000a0;&#x000b1;&#x000a0;2<sup>b</sup></td><td char="&#x000b1;" align="char">99&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">98&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">84&#x000a0;&#x000b1;&#x000a0;2<sup>$</sup></td><td char="&#x000b1;" align="char">78&#x000a0;&#x000b1;&#x000a0;3<sup>b</sup></td><td char="&#x000b1;" align="char">52&#x000a0;&#x000b1;&#x000a0;2</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">94&#x000a0;&#x000b1;&#x000a0;5</td><td char="&#x000b1;" align="char">106&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">114&#x000a0;&#x000b1;&#x000a0;3<sup>b</sup></td><td char="&#x000b1;" align="char">103&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">103&#x000a0;&#x000b1;&#x000a0;4</td><td char="&#x000b1;" align="char">87&#x000a0;&#x000b1;&#x000a0;3<sup>$</sup></td><td char="&#x000b1;" align="char">82&#x000a0;&#x000b1;&#x000a0;6<sup>b</sup></td><td char="&#x000b1;" align="char">51&#x000a0;&#x000b1;&#x000a0;8</td></tr></tbody></table><table-wrap-foot><p>Values are mean&#x000a0;&#x000b1;&#x000a0;SEM for <italic>n</italic>&#x000a0;=&#x000a0;6 per group. There was no statistical difference in FiO<sub>2</sub> and resulting CaO<sub>2</sub> across the four hypoxic conditions</p><p><italic>Recovery-30</italic> and<italic> recovery-60</italic> are measurement points at 30 and 60&#x000a0;min of normoxic recovery,<italic> FiO</italic><sub><italic>2</italic></sub> inspiratory oxygen fraction,<italic> CaO</italic><sub><italic>2</italic></sub> arterial oxygen content,<italic> PaO</italic><sub><italic>2</italic></sub> arterial oxygen partial pressure,<italic> SaO</italic><sub><italic>2</italic></sub> arterial oxygen saturation,<italic> PaCO</italic><sub><italic>2</italic></sub> arterial carbon dioxide partial pressure,<italic> pH</italic> arterial pH,<italic> HCO</italic><sub arrange="stack"><italic>3</italic></sub><sup arrange="stack">&#x02212;</sup> arterial bicarbonate concentration,<italic> lactate</italic> arterial lactate concentration,<italic> glucose</italic> arterial glucose concentration</p><p>*&#x000a0;Significant drug effects of LEVO and <sup>$</sup> GLIB</p><p><sup>a</sup>No difference between hypoxia episodes</p><p><sup>b</sup>Significant difference within one group&#x02019;s hypoxia episodes</p><p><sup>c</sup>Significant difference between the two groups&#x02019; hypoxia episodes</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec18"><title>Hypoxia in unpretreated animals</title><p>In our hypoxia model, reduction of FiO<sub>2</sub> from 0.3 to 0.11 in unpretreated animals decreased PaO<sub>2</sub> from 133&#x000a0;&#x000b1;&#x000a0;9 to 39&#x000a0;&#x000b1;&#x000a0;1&#x000a0;Torr and thereby SaO<sub>2</sub> from 98&#x000a0;&#x000b1;&#x000a0;0 to 68&#x000a0;&#x000b1;&#x000a0;1%. Together with an unchanged Hb (stable at ~12.5&#x000a0;g&#x000a0;dL<sup>&#x02212;1</sup>, data not shown) this decreased CaO<sub>2</sub> from 17.3&#x000a0;&#x000b1;&#x000a0;0.8 to 11.7&#x000a0;&#x000b1;&#x000a0;0.6&#x000a0;mL&#x000a0;dL<sup>&#x02212;1</sup> (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). At the regional level, gastromucosal &#x003bc;HbO<sub>2</sub> decreased from 56&#x000a0;&#x000b1;&#x000a0;3 to 32&#x000a0;&#x000b1;&#x000a0;4% (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). DO<sub>2</sub> decreased from 14&#x000a0;&#x000b1;&#x000a0;1 to 9&#x000a0;&#x000b1;&#x000a0;1&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>, since CaO<sub>2</sub> decreased without compensatory increase in CO. However, systemic VO<sub>2</sub> was preserved at ~3.5&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Mechanical ventilation adjusted to maintain etCO<sub>2</sub> at 35&#x000a0;Torr maintained PaCO<sub>2</sub> at 35&#x02013;38&#x000a0;Torr. Acid/base-related variables remained stable, i.e., pH at 7.35&#x02013;7.37 and HCO<sub>3</sub><sup>&#x02212;</sup> at ~20&#x000a0;mmol&#x000a0;L<sup>&#x02212;1</sup>. Glucose and lactate (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) and all measured electrolytes remained close to baseline (data not shown).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Gastric mucosal microcirculatory hemoglobin oxygenation (&#x003bc;HbO<sub>2</sub>). Gastromucosal &#x003bc;HbO<sub>2</sub> during normoxia (FiO<sub>2</sub> ~0.3, <italic>thin outlined bars</italic>) and the two hypoxia episodes (FiO<sub>2&#x000a0;</sub>~&#x000a0;0.1, <italic>bold outlined bars</italic>) of the two experimental groups I (<italic>left bar</italic> per condition) and II (<italic>right bar</italic> per condition). Levosimendan was not given in group I, thus condition LEVO in group I is not determined (n.d.). Filling patterns: <italic>gray</italic> no pretreatment, <italic>downward stripes</italic> levosimendan (LEVO) pretreatment, <italic>upward stripes</italic> glibenclamide (GLIB) pretreatment,<italic> hatches</italic> levosimendan&#x000a0;+&#x000a0;glibenclamide pretreatment.<italic> Recovery-30</italic> and<italic> recovery-60</italic> are measurement points at 30 and 60&#x000a0;min of normoxic recovery. Mean&#x000a0;&#x000b1;&#x000a0;SEM for <italic>n</italic>&#x000a0;=&#x000a0;6 per group. <sup>a</sup>No difference between hypoxia episodes, <sup>b</sup>significant difference within one group&#x02019;s hypoxia episodes, <sup>c</sup>significant difference between the two groups&#x02019; hypoxia episodes, *&#x000a0;significant drug effects of LEVO and <sup>$</sup>&#x000a0;GLIB</p></caption><graphic xlink:href="134_2011_2144_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Systemic hemodynamic variables and systemic oxygen metabolism</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="left">Condition</th><th align="left">Baseline</th><th align="left">LEVO</th><th align="left">Hypoxia-1</th><th align="left">Recovery-30</th><th align="left">Recovery-60</th><th align="left">GLIB</th><th align="left">Hypoxia-2</th><th align="left">Recovery-30</th></tr></thead><tbody><tr><td align="left" rowspan="2">SV (mL)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">18&#x000a0;&#x000b1;&#x000a0;1</td><td align="left">(n.d.)</td><td char="&#x000b1;" align="char">17&#x000a0;&#x000b1;&#x000a0;1<sup>b</sup></td><td char="&#x000b1;" align="char">18&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">18&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">17&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">15&#x000a0;&#x000b1;&#x000a0;1<sup>b</sup></td><td char="&#x000b1;" align="char">17&#x000a0;&#x000b1;&#x000a0;1</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">20&#x000a0;&#x000b1;&#x000a0;1</td><td align="left">22&#x000a0;&#x000b1;&#x000a0;1*</td><td char="&#x000b1;" align="char">21&#x000a0;&#x000b1;&#x000a0;1<sup>b</sup></td><td char="&#x000b1;" align="char">22&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">22&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">21&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">21&#x000a0;&#x000b1;&#x000a0;1<sup>b</sup></td><td char="&#x000b1;" align="char">20&#x000a0;&#x000b1;&#x000a0;1</td></tr><tr><td align="left" rowspan="2">HR (bpm)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">116&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">(n.d.)</td><td char="&#x000b1;" align="char">121&#x000a0;&#x000b1;&#x000a0;2<sup>a</sup></td><td char="&#x000b1;" align="char">114&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">113&#x000a0;&#x000b1;&#x000a0;3</td><td char="&#x000b1;" align="char">112&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">117&#x000a0;&#x000b1;&#x000a0;2<sup>a</sup></td><td char="&#x000b1;" align="char">112&#x000a0;&#x000b1;&#x000a0;2</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">111&#x000a0;&#x000b1;&#x000a0;6</td><td align="left">117&#x000a0;&#x000b1;&#x000a0;6</td><td char="&#x000b1;" align="char">126&#x000a0;&#x000b1;&#x000a0;4<sup>a</sup></td><td char="&#x000b1;" align="char">116&#x000a0;&#x000b1;&#x000a0;5</td><td char="&#x000b1;" align="char">117&#x000a0;&#x000b1;&#x000a0;5</td><td char="&#x000b1;" align="char">116&#x000a0;&#x000b1;&#x000a0;4</td><td char="&#x000b1;" align="char">124&#x000a0;&#x000b1;&#x000a0;4<sup>a</sup></td><td char="&#x000b1;" align="char">119&#x000a0;&#x000b1;&#x000a0;4</td></tr><tr><td align="left" rowspan="2">MAP (mmHg)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">62&#x000a0;&#x000b1;&#x000a0;3</td><td align="left">(n.d.)</td><td char="&#x000b1;" align="char">66&#x000a0;&#x000b1;&#x000a0;4<sup>a</sup></td><td char="&#x000b1;" align="char">63&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">62&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">65&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">62&#x000a0;&#x000b1;&#x000a0;4<sup>a</sup></td><td char="&#x000b1;" align="char">63&#x000a0;&#x000b1;&#x000a0;1</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">61&#x000a0;&#x000b1;&#x000a0;1</td><td align="left">62&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">67&#x000a0;&#x000b1;&#x000a0;4<sup>a</sup></td><td char="&#x000b1;" align="char">64&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">62&#x000a0;&#x000b1;&#x000a0;1</td><td char="&#x000b1;" align="char">61&#x000a0;&#x000b1;&#x000a0;2</td><td char="&#x000b1;" align="char">65&#x000a0;&#x000b1;&#x000a0;6<sup>a</sup></td><td char="&#x000b1;" align="char">61&#x000a0;&#x000b1;&#x000a0;2</td></tr><tr><td align="left" rowspan="2">SVR (dyn&#x000a0;s&#x000a0;cm<sup>&#x02212;5</sup>)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">2,468&#x000a0;&#x000b1;&#x000a0;235</td><td align="left">(n.d.)</td><td char="&#x000b1;" align="char">2,647&#x000a0;&#x000b1;&#x000a0;165<sup>c</sup></td><td char="&#x000b1;" align="char">2,502&#x000a0;&#x000b1;&#x000a0;131</td><td char="&#x000b1;" align="char">2,403&#x000a0;&#x000b1;&#x000a0;127</td><td char="&#x000b1;" align="char">2,792&#x000a0;&#x000b1;&#x000a0;224<sup>$</sup></td><td char="&#x000b1;" align="char">2,765&#x000a0;&#x000b1;&#x000a0;118<sup>c</sup></td><td char="&#x000b1;" align="char">2,720&#x000a0;&#x000b1;&#x000a0;113</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">2,295&#x000a0;&#x000b1;&#x000a0;127</td><td align="left">1,943&#x000a0;&#x000b1;&#x000a0;87*</td><td char="&#x000b1;" align="char">2,039&#x000a0;&#x000b1;&#x000a0;162<sup>c</sup></td><td char="&#x000b1;" align="char">2,024&#x000a0;&#x000b1;&#x000a0;98</td><td char="&#x000b1;" align="char">1,969&#x000a0;&#x000b1;&#x000a0;84</td><td char="&#x000b1;" align="char">2,006&#x000a0;&#x000b1;&#x000a0;78</td><td char="&#x000b1;" align="char">2,014&#x000a0;&#x000b1;&#x000a0;178<sup>c</sup></td><td char="&#x000b1;" align="char">2,071&#x000a0;&#x000b1;&#x000a0;93</td></tr><tr><td align="left" rowspan="2">VO<sub>2</sub> (mL&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>)</td><td align="left">Group I</td><td char="&#x000b1;" align="char">3.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td align="left">(n.d.)</td><td char="&#x000b1;" align="char">3.4&#x000a0;&#x000b1;&#x000a0;0.1<sup>a</sup></td><td char="&#x000b1;" align="char">3.7&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">3.7&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">4.1&#x000a0;&#x000b1;&#x000a0;0.1<sup>$</sup></td><td char="&#x000b1;" align="char">3.6&#x000a0;&#x000b1;&#x000a0;0.1<sup>a</sup></td><td char="&#x000b1;" align="char">4.2&#x000a0;&#x000b1;&#x000a0;0.1</td></tr><tr><td align="left">Group II</td><td char="&#x000b1;" align="char">3.3&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">3.7&#x000a0;&#x000b1;&#x000a0;0.2</td><td char="&#x000b1;" align="char">3.3&#x000a0;&#x000b1;&#x000a0;0.3<sup>a</sup></td><td char="&#x000b1;" align="char">3.5&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">3.6&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">3.8&#x000a0;&#x000b1;&#x000a0;0.1</td><td char="&#x000b1;" align="char">3.5&#x000a0;&#x000b1;&#x000a0;0.2<sup>a</sup></td><td char="&#x000b1;" align="char">3.5&#x000a0;&#x000b1;&#x000a0;0.2</td></tr></tbody></table><table-wrap-foot><p>Values are mean&#x000a0;&#x000b1;&#x000a0;SEM for <italic>n</italic>&#x000a0;=&#x000a0;6 per group</p><p><italic>Recovery-30</italic> and<italic> recovery-60</italic> are measurement points at 30 and 60&#x000a0;min of normoxic recovery,<italic> HR</italic> heart rate,<italic> MAP</italic> mean arterial pressure,<italic> SVR</italic> systemic vascular resistance,<italic> VO</italic><sub><italic>2</italic></sub> systemic oxygen consumption</p><p>*&#x000a0;Significant drug effects of LEVO and <sup>$</sup>&#x000a0;GLIB</p><p><sup>a</sup>No difference between hypoxia episodes</p><p><sup>b</sup>Significant difference within one group&#x02019;s hypoxia episodes</p><p><sup>c</sup>Significant difference between the two groups&#x02019; hypoxia episodes</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec19"><title>Hypoxia in GLIB-pretreated animals</title><p>GLIB pretreatment, used to block GLIB-sensitive K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels, significantly increased SVR and significantly affected some blood-derived variables, e.g., it decreased arterial glucose concentration (Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>).</p><p>Hypoxia after GLIB pretreatment resulted in a similar decreased CaO<sub>2</sub> (11.1&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;mL&#x000a0;dL<sup>&#x02212;1</sup>), compared to unpretreated animals (11.7&#x000a0;&#x000b1;&#x000a0;0.6&#x000a0;mL&#x000a0;dL<sup>&#x02212;1</sup>). Also, no statistical differences were observed in ventilation- and acid/base-derived parameters (PaCO<sub>2</sub>, pH, and BE) and the O<sub>2</sub>-related variables &#x003bc;HbO<sub>2</sub>, DO<sub>2</sub>, and VO<sub>2</sub> between these two hypoxic conditions. However, in GLIB-pretreated hypoxia, arterial lactate was significantly lower (~1.2&#x000a0;mmol&#x000a0;L<sup>&#x02212;1</sup>) compared to unpretreated hypoxia (~2.6&#x000a0;mmol&#x000a0;L<sup>&#x02212;1</sup>). Systemic hemodynamics (i.e., MAP and CO) did not differ between these two hypoxic episodes. Arterial electrolytes did not differ, and arterial glucose was significantly lower in GLIB-pretreated hypoxia (~80&#x000a0;mg&#x000a0;dL<sup>&#x02212;1</sup>) compared to unpretreated hypoxia (~110&#x000a0;mg&#x000a0;dL<sup>&#x02212;1</sup>) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec20"><title>Hypoxia in LEVO-pretreated animals</title><p>LEVO pretreatment at the macrocirculatory level significantly increased SV, CO, +d<italic>P</italic>/d<italic>t</italic><sub>max</sub>, and DO<sub>2</sub> and decreased SVR, without significant changes in HR. At the microcirculatory level, LEVO pretreatment significantly increased &#x003bc;HbO<sub>2</sub> at a stable systemic SaO<sub>2</sub>.</p><p>Hypoxia after LEVO pretreatment resulted in a similar decrease in CaO<sub>2</sub> to 10.3&#x000a0;&#x000b1;&#x000a0;0.5&#x000a0;mL&#x000a0;dL<sup>&#x02212;1</sup>, compared to unpretreated animals. In LEVO-pretreated hypoxia, CO was significantly higher compared to unpretreated hypoxia, i.e., ~100 versus ~80&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>). This was not paralleled by systemic VO<sub>2</sub>, which was comparable to unpretreated animals at ~3.5&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>. Also gastromucosal &#x003bc;HbO<sub>2</sub> equally decreased in both unpretreated and LEVO-pretreated animals to ~30% (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Systemic vascular resistance was significantly lower in LEVO-pretreated hypoxia, compared to unpretreated hypoxia.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Cardiac output. Cardiac output during normoxia (FiO<sub>2</sub> ~0.3, <italic>thin outlined bars</italic>) and the two hypoxia episodes (FiO<sub>2</sub> ~0.1, <italic>bold outlined bars</italic>) of the two experimental groups I (<italic>left bar</italic> per condition) and II (<italic>right bar</italic> per condition). Levosimendan was not given in group I, thus condition LEVO in group I is not determined (n.d.). Filling patterns: <italic>gray</italic> no pretreatment, <italic>downward stripes</italic> levosimendan (LEVO) pretreatment, <italic>upward stripes</italic> glibenclamide (GLIB) pretreatment,<italic> hatches</italic> levosimendan&#x000a0;+&#x000a0;glibenclamide pretreatment.<italic> Recovery-30</italic> and<italic> recovery-60</italic> are measurement points at 30 and 60&#x000a0;min of normoxic recovery. Mean&#x000a0;&#x000b1;&#x000a0;SEM for <italic>n</italic>&#x000a0;=&#x000a0;6 per group. <sup>a</sup>No difference between hypoxia episodes, <sup>b</sup>significant difference within one group&#x02019;s hypoxia episodes, <sup>c</sup>significant difference between the two groups&#x02019; hypoxia episodes, *significant drug effects of LEVO and <sup>$</sup>GLIB</p></caption><graphic xlink:href="134_2011_2144_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Pressure-curve-derived contractility, +d<italic>P</italic>/d<italic>t</italic><sub>max</sub>. Resulting +d<italic>P</italic>/d<italic>t</italic><sub>max</sub> during normoxia (FiO<sub>2</sub> ~0.3, <italic>thin outlined bars</italic>) and the two hypoxia episodes (FiO<sub>2</sub> ~0.1, <italic>bold outlined bars</italic>) of the two experimental groups I (<italic>left bar</italic> per condition) and II (<italic>right bar</italic> per condition). Levosimendan was not given in group I, thus condition LEVO in group I is not determined (n.d.). Filling patterns: <italic>gray</italic> no pretreatment, <italic>downward stripes</italic> levosimendan (LEVO) pretreatment, <italic>upward stripes</italic> glibenclamide (GLIB) pretreatment,<italic> hatches</italic> levosimendan&#x000a0;+&#x000a0;glibenclamide pretreatment.<italic> Recovery-30</italic> and<italic> recovery-60</italic> are measurement points at 30 and 60&#x000a0;min of normoxic recovery. Mean&#x000a0;&#x000b1;&#x000a0;SEM for <italic>n</italic>&#x000a0;=&#x000a0;6 per group. <sup>a</sup>No difference between hypoxia episodes, <sup>b</sup>significant difference within one group&#x02019;s hypoxia episodes, <sup>c</sup>significant difference between the two groups&#x02019; hypoxia episodes, *significant drug effects of LEVO and <sup>$</sup>GLIB</p></caption><graphic xlink:href="134_2011_2144_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec21"><title>Hypoxia in LEVO- plus GLIB-pretreated animals</title><p>Administration of GLIB during LEVO infusion induced significant effects, e.g., GLIB significantly decreased serum glucose from 103&#x000a0;&#x000b1;&#x000a0;4 to 87&#x000a0;&#x000b1;&#x000a0;3&#x000a0;mg&#x000a0;dL<sup>&#x02212;1</sup> (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).</p><p>Hypoxic ventilation under combined pretreatment with LEVO and GLIB resulted in a PaO<sub>2</sub> of 32&#x000a0;Torr. During hypoxia with LEVO&#x000a0;+&#x000a0;GLIB pretreatment, CaO<sub>2</sub> tended to be lower compared to unpretreated hypoxia (9.4&#x000a0;&#x000b1;&#x000a0;0.9 vs. 11.7&#x000a0;&#x000b1;&#x000a0;0.6&#x000a0;mL&#x000a0;dL<sup>&#x02212;1</sup>), however, without statistical significance. CO was significantly higher than during hypoxia in solely GLIB-pretreated animals and did not differ from solely LEVO-pretreated animals (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). SVR was significantly lower in LEVO&#x000a0;+&#x000a0;GLIB-pretreated hypoxia compared to GLIB-pretreated hypoxia. Systemic VO<sub>2</sub> was comparable to all other hypoxic conditions at ~3.5&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup>. Glucose, as expected, significantly decreased with GLIB.</p></sec><sec id="Sec22"><title>Thermodilution-derived variables</title><p>Transpulmonary thermodilution (PiCCO) revealed no significant differences in the estimated blood volumes ITBV (~20&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>) and GEDV (~16&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>) or estimated EWLV (~9&#x000a0;mL&#x000a0;kg<sup>&#x02212;1</sup>) between the four hypoxemia conditions (data not shown).</p></sec></sec><sec id="Sec23"><title>Discussion</title><p>For the present study we developed a model of moderate hypoxic hypoxemia, adapting reported canine hypoxia models [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Repetitive experiments were performed in a randomized mode on healthy, chronically instrumented dogs with intervals of &#x02265;2&#x000a0;weeks to exclude carryover effects and to minimize interindividual differences. Furthermore, the use of chronically instrumented animals avoided acute, surgical instrumentation and thus confounders such as endocrine stress responses to surgery. In addition, our model allowed us to study the animals during sedation with sevoflurane and rocuronium alone, i.e., without need for analgesics or other confounding drugs [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>In this study, two subsequent episodes of hypoxia were induced per group. While the first hypoxic episode served to elucidate the effect of LEVO pretreatment, the second hypoxic episode served to elucidate the role of K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels (by subsequently adding GLIB pretreatment, reported to block GLIB-sensitive K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]). Between the two hypoxic episodes, an extended normoxic period was interposed to allow complete recovery of measured variables. In addition, to exclude the possibility that the first hypoxic episode was affecting the second with respect to measured variables, pilot experiments were performed, comparing a first with a second hypoxic period without adding any medication (i.e., no GLIB) in between. These pilot experiments demonstrated no differences between the first and second hypoxic episode, with respect to the measured variables.</p><p>Gastromucosal &#x003bc;HbO<sub>2</sub> was continuously measured by reflectance spectrophotometry [<xref ref-type="bibr" rid="CR43">43</xref>], with the light guide nontraumatically introduced via an orogastric tube [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. Reflectance spectrophotometry allows determination of microcirculatory oxygen availability [<xref ref-type="bibr" rid="CR44">44</xref>], and gastric endoluminal reflectance spectroscopy has been reported predominantly to measure capillary hemoglobin oxygenation of the mucosa [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p>Both hypoxia and the administered drugs may affect pulmonary endothelial permeability. Thus, we assessed EVLW by the PiCCO system, a method validated in anaesthetized dogs [<xref ref-type="bibr" rid="CR37">37</xref>]. The EVLW data do not support pulmonary edema as cause of the small but significant differences in PaO<sub>2</sub> between distinct hypoxia conditions (i.e., slightly lower with LEVO and/or GLIB), rendering an altered pulmonary shunt, as also reported for other vasoactive agents [<xref ref-type="bibr" rid="CR46">46</xref>], as the most likely explanation.</p><p>LEVO appears to be a promising candidate agent to support the cardiocirculatory system during hypoxemia, particularly because circulatory stimulation by LEVO is reportedly independent of metabolic stimulation [<xref ref-type="bibr" rid="CR9">9</xref>]. Our data support this concept, demonstrating that LEVO pretreatment resulted in improved systemic circulation (CO) also during hypoxemia without fueling aerobic (VO<sub>2</sub>) metabolism. Thus, the pattern of increased CO at stable VO<sub>2</sub> was present also during hypoxemia in LEVO-pretreated subjects and, in turn, other factors triggered by hypoxemia, e.g., changed pharmacology [<xref ref-type="bibr" rid="CR47">47</xref>], did not alter this pattern. Measured key modulators of vascular tone (PaCO<sub>2</sub>, pH, temperature, arterial [K<sup>+</sup>] and [Ca<sup>2+</sup>]) did not differ between the hypoxemic episodes, supporting that LEVO-specific mechanisms cause the differences in cardiovascular response.</p><p>The present study was designed to suggest a concept to improve the condition of the subject before an anticipated hypoxemia evolves; however, the majority of clinical hypoxemia episodes occur unexpectedly. Therefore, future studies will have to demonstrate if our findings are confirmed in the clinically more likely setting, i.e., with LEVO administered in a therapeutic rather than prophylactic approach [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p>Increased CO during hypoxemia after LEVO pretreatment, compared to unpretreated hypoxemia, was associated with an increased +d<italic>P</italic>/d<italic>t</italic><sub>max</sub>, compatible with positive inotropic effects of LEVO by myocardial Ca<sup>2+</sup> sensitizing. LEVO, besides acting as a cardiac Ca<sup>2+</sup> sensitizer, also activates K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels. Physiologically, various K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel isoforms exist, classified by their respective sulfonylurea receptors (SUR) in pancreatic &#x003b2;-cells (SUR-1), and striated (SUR-2A) and smooth muscle cells (SUR-2B). Vascular smooth muscle K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels link regional metabolism to perfusion, since intracellular ATP depletion (e.g., during hypoxia) triggers these channels, leading to hyperpolarization and thus vasorelaxation [<xref ref-type="bibr" rid="CR8">8</xref>]. However, excessive activation of these K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels is involved in multiple pathological vasodilatory states, e.g., septic shock [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Thus, whether pharmacological activation of K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels under pathological conditions by LEVO is beneficial might also depend on the individual vasodilatory state. Pharmacologically, K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels are antagonized by sulfonylurea derivatives, with GLIB (glyburide) reported to unspecifically block all receptor isoforms, SUR-1, SUR-2A, and SUR-2B. GLIB has been reported to be effective as a K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel antagonist in dogs before, in similar dosages as applied in the present study [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Activity of GLIB in our model is suggested by the hypoglycemic response after GLIB pretreatment (SUR-1 effect), with arterial glucose decreased from baseline values of ~100 to ~50&#x000a0;mg&#x000a0;dL<sup>&#x02212;1</sup> (end of experiments). In addition, GLIB pretreatment significantly increased SVR, suggesting (partial) blockade of vascular K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels.</p><p>Thus, although GLIB pretreatment significantly increased SVR in this model, the demonstrated marked hypoglycemic effect of GLIB may limit its clinical use.</p><p>Combined GLIB&#x000a0;+&#x000a0;LEVO pretreatment resulted in significantly higher CO and +d<italic>P</italic>/d<italic>t</italic><sub>max</sub> than GLIB pretreatment alone during hypoxemia, compatible with the notion that mechanisms other than K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channel opening contribute to LEVO effects, also during hypoxemia. Besides Ca<sup>2+</sup> (re-)sensitization, LEVO&#x02019;s action as a phosphodiesterase (PDE) inhibitor could also contribute. In this regard, other PDE-III inhibitors have demonstrated positive systemic and regional gastrointestinal mucosal effects during hypoxemia [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p>Despite significant systemic differences, regional gastromucosal oxygenation did not differ between LEVO-pretreated and unpretreated hypoxemia, which decreased equally to ~30%. Regional regulation of mucosal perfusion during hypoxemia could overrule the effects of LEVO, despite an increased CO and reduced SVR in LEVO-pretreated hypoxia. A possible mechanism is that local hypoxia activates vasodilatory K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels to such extents that LEVO can not confer significant additional vasodilation. Indeed after GLIB pretreatment, administered to block these vasodilatory K<sub arrange="stack">ATP</sub><sup arrange="stack">+</sup> channels and thus to induce vasoconstriction, we observed clear trends towards lower &#x003bc;HbO<sub>2</sub> both in LEVO-pretreated (from 32&#x000a0;&#x000b1;&#x000a0;4 to 24&#x000a0;&#x000b1;&#x000a0;4%) and unpretreated hypoxemia (from 30&#x000a0;&#x000b1;&#x000a0;4 to 25&#x000a0;&#x000b1;&#x000a0;3%). Interestingly, also in both groups arterial lactate concentrations were significantly lower after GLIB pretreatment. Since arterial pH and the other acid/base-related variables remained close to baseline under all hypoxemia conditions, we doubt that these significant differences in lactate concentration are caused by different perfusion states, rendering direct metabolic effects of GLIB more likely to contribute.</p><p>LEVO is clinically indicated for the treatment of chronic or acute cardiac failure, with promising results [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], and indications have already extended to septic and toxic cardiac depression [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. If our experimental data apply to the clinical setting, LEVO pretreatment may also be an option to support the cardiovascular system during hypoxemia, without fueling VO<sub>2</sub>, without aggravating systemic anaerobiosis markers, and without further compromising the regional gastromucosal oxygenation. Further studies will have to extend these experimental results to other hypoxia models and ultimately to the clinical setting.</p></sec></body><back><ack><p><bold>Conflict of interest</bold> None of the authors is affiliated with any company involved. Funding came from departmental sources.</p><p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilbert</surname><given-names>G</given-names></name><name><surname>Gruson</surname><given-names>D</given-names></name><name><surname>Vargas</surname><given-names>F</given-names></name><name><surname>Valentino</surname><given-names>R</given-names></name><name><surname>Favier</surname><given-names>JC</given-names></name><name><surname>Portel</surname><given-names>L</given-names></name><name><surname>Gbikpi-Benissan</surname><given-names>G</given-names></name><name><surname>Cardinaud</surname><given-names>JP</given-names></name></person-group><article-title>Bronchoscopy with bronchoalveolar lavage via the laryngeal mask airway in high-risk hypoxemic immunosuppressed patients</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><fpage>249</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1097/00003246-200102000-00004</pub-id><pub-id pub-id-type="pmid">11246301</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Amraoui</surname><given-names>J</given-names></name><name><surname>Lefrant</surname><given-names>JY</given-names></name><name><surname>Arich</surname><given-names>C</given-names></name><name><surname>Cohendy</surname><given-names>R</given-names></name><name><surname>Landreau</surname><given-names>L</given-names></name><name><surname>Calvet</surname><given-names>Y</given-names></name><name><surname>Capdevila</surname><given-names>X</given-names></name><name><surname>Mahamat</surname><given-names>A</given-names></name><name><surname>Eledjam</surname><given-names>JJ</given-names></name></person-group><article-title>Clinical practice and risk factors for immediate complications of endotracheal intubation in the intensive care unit</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>2355</fpage><lpage>2361</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000233879.58720.87</pub-id><pub-id pub-id-type="pmid">16850003</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mort</surname><given-names>TC</given-names></name></person-group><article-title>Preoxygenation in critically ill patients requiring emergency tracheal intubation</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>2672</fpage><lpage>2675</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000187131.67594.9E</pub-id><pub-id pub-id-type="pmid">16276196</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sud</surname><given-names>S</given-names></name><name><surname>Friedrich</surname><given-names>JO</given-names></name><name><surname>Taccone</surname><given-names>P</given-names></name><name><surname>Polli</surname><given-names>F</given-names></name><name><surname>Adhikari</surname><given-names>NK</given-names></name><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Pesenti</surname><given-names>A</given-names></name><name><surname>Gu&#x000e9;rin</surname><given-names>C</given-names></name><name><surname>Mancebo</surname><given-names>J</given-names></name><name><surname>Curley</surname><given-names>MA</given-names></name><name><surname>Fernandez</surname><given-names>R</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Beuret</surname><given-names>P</given-names></name><name><surname>Voggenreiter</surname><given-names>G</given-names></name><name><surname>Sud</surname><given-names>M</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Gattinoni</surname><given-names>L</given-names></name></person-group><article-title>Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia</article-title><source>Intensive Care Med</source><year>2010</year><volume>36</volume><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1748-1</pub-id><pub-id pub-id-type="pmid">20130832</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaobornyj</surname><given-names>T</given-names></name><name><surname>Gonzales</surname><given-names>GF</given-names></name><name><surname>Valdez</surname><given-names>LB</given-names></name></person-group><article-title>Mitochondrial contribution to the molecular mechanism of heart acclimatization to chronic hypoxia</article-title><source>Front Biosci</source><year>2007</year><volume>12</volume><fpage>1247</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.2741/2143</pub-id><pub-id pub-id-type="pmid">17127451</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>DG</given-names></name><name><surname>Orchard</surname><given-names>CH</given-names></name></person-group><article-title>Myocardial contractile function during ischemia and hypoxia</article-title><source>Circ Res</source><year>1987</year><volume>60</volume><fpage>153</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">3552284</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>SM</given-names></name><name><surname>Westfall</surname><given-names>MV</given-names></name><name><surname>Fomicheva</surname><given-names>EV</given-names></name><name><surname>Hoyer</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>La Cross</surname><given-names>NC</given-names></name><name><surname>D&#x02019;Alecy</surname><given-names>LG</given-names></name><name><surname>Ingwall</surname><given-names>JS</given-names></name><name><surname>Metzger</surname><given-names>JM</given-names></name></person-group><article-title>Histidine button engineered into cardiac troponin I protects the ischemic and failing heart</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/nm1346</pub-id><pub-id pub-id-type="pmid">16429145</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>The pathogenesis of vasodilatory shock</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>588</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1056/NEJMra002709</pub-id><pub-id pub-id-type="pmid">11529214</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarte</surname><given-names>LA</given-names></name><name><surname>Picker</surname><given-names>O</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Fournell</surname><given-names>A</given-names></name><name><surname>Scheeren</surname><given-names>TW</given-names></name></person-group><article-title>Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000150653.89451.6F</pub-id><pub-id pub-id-type="pmid">15644660</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathie</surname><given-names>RT</given-names></name><name><surname>Blumgart</surname><given-names>LH</given-names></name></person-group><article-title>Effect of denervation on the hepatic haemodynamic response to hypercapnia and hypoxia in the dog</article-title><source>Pflugers Arch</source><year>1983</year><volume>397</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1007/BF00582055</pub-id><pub-id pub-id-type="pmid">6866732</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JM</given-names></name><name><surname>Metcalfe</surname><given-names>JD</given-names></name></person-group><article-title>Analysis of factors that contribute to cardiovascular changes induced in the cat by graded levels of systemic hypoxia</article-title><source>J Physiol</source><year>1989</year><volume>412</volume><fpage>429</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">2600840</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>RM</given-names></name><name><surname>Robertson</surname><given-names>TP</given-names></name><name><surname>Twort</surname><given-names>CH</given-names></name><name><surname>Ward</surname><given-names>JP</given-names></name></person-group><article-title>Hypoxic vasoconstriction in rat pulmonary and mesenteric arteries</article-title><source>Am J Physiol</source><year>1994</year><volume>266</volume><fpage>223</fpage><lpage>231</lpage></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandek</surname><given-names>A</given-names></name><name><surname>Rauchhaus</surname><given-names>M</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Haehling</surname><given-names>S</given-names></name></person-group><article-title>The emerging role of the gut in chronic heart failure</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2008</year><volume>11</volume><fpage>632</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1097/MCO.0b013e32830a4c6e</pub-id><pub-id pub-id-type="pmid">18685461</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Morisaki</surname><given-names>H</given-names></name><name><surname>Ai</surname><given-names>K</given-names></name><name><surname>Kosugi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Serita</surname><given-names>R</given-names></name><name><surname>Kotake</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>J</given-names></name></person-group><article-title>Olprinone, a phosphodiesterase III inhibitor, reduces gut mucosal injury and portal endotoxin level during acute hypoxia in rabbits</article-title><source>Anesthesiology</source><year>2003</year><volume>98</volume><fpage>1407</fpage><lpage>1414</lpage><pub-id pub-id-type="doi">10.1097/00000542-200306000-00016</pub-id><pub-id pub-id-type="pmid">12766650</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>A</given-names></name><name><surname>Bradford</surname><given-names>C</given-names></name><name><surname>McCaffrey</surname><given-names>J</given-names></name><name><surname>Bagshaw</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name></person-group><article-title>Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials</article-title><source>Int J Cardiol</source><year>2010</year><volume>138</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2008.08.020</pub-id><pub-id pub-id-type="pmid">18817994</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landoni</surname><given-names>G</given-names></name><name><surname>Mizzi</surname><given-names>A</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G</given-names></name><name><surname>Bignami</surname><given-names>E</given-names></name><name><surname>Prati</surname><given-names>P</given-names></name><name><surname>Ajello</surname><given-names>V</given-names></name><name><surname>Marino</surname><given-names>G</given-names></name><name><surname>Guarracino</surname><given-names>F</given-names></name><name><surname>Zangrillo</surname><given-names>A</given-names></name></person-group><article-title>Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies</article-title><source>Minerva Anestesiol</source><year>2010</year><volume>76</volume><fpage>276</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">20332741</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parissis</surname><given-names>JT</given-names></name><name><surname>Rafouli-Stergiou</surname><given-names>P</given-names></name><name><surname>Stasinos</surname><given-names>V</given-names></name><name><surname>Psarogiannakopoulos</surname><given-names>P</given-names></name><name><surname>Mebazaa</surname><given-names>A</given-names></name></person-group><article-title>Inotropes in cardiac patients: update 2011</article-title><source>Curr Opin Crit Care</source><year>2010</year><volume>16</volume><fpage>432</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e32833e10fb</pub-id><pub-id pub-id-type="pmid">20711077</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leppikangas</surname><given-names>H</given-names></name><name><surname>Ruokonen</surname><given-names>E</given-names></name><name><surname>Rutanen</surname><given-names>J</given-names></name><name><surname>Kiviniemi</surname><given-names>V</given-names></name><name><surname>Lindgren</surname><given-names>L</given-names></name><name><surname>Kurola</surname><given-names>J</given-names></name></person-group><article-title>Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study</article-title><source>Ann Emerg Med</source><year>2009</year><volume>54</volume><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2009.06.512</pub-id><pub-id pub-id-type="pmid">19766354</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creteur</surname><given-names>J</given-names></name><name><surname>Bouckaert</surname><given-names>Y</given-names></name><name><surname>Melot</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><fpage>790</fpage><pub-id pub-id-type="doi">10.1007/s00134-006-0130-9</pub-id><pub-id pub-id-type="pmid">16555067</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBacker</surname><given-names>D</given-names></name><name><surname>Taccone</surname><given-names>FS</given-names></name><name><surname>Radermacher</surname><given-names>P</given-names></name></person-group><article-title>Levosimendan in septic shock: another piece in the puzzle, but many pieces are still lacking</article-title><source>Intensive Care Med</source><year>2007</year><volume>33</volume><fpage>403</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1007/s00134-006-0520-z</pub-id><pub-id pub-id-type="pmid">17262189</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubin</surname><given-names>A</given-names></name><name><surname>Murias</surname><given-names>G</given-names></name><name><surname>Sottile</surname><given-names>JP</given-names></name><name><surname>Pozo</surname><given-names>MO</given-names></name><name><surname>Bar&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Edul</surname><given-names>VS</given-names></name><name><surname>Canales</surname><given-names>HS</given-names></name><name><surname>Etcheverry</surname><given-names>G</given-names></name><name><surname>Maskin</surname><given-names>B</given-names></name><name><surname>Estenssoro</surname><given-names>E</given-names></name></person-group><article-title>Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study</article-title><source>Intensive Care Med</source><year>2007</year><volume>33</volume><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1007/s00134-006-0519-5</pub-id><pub-id pub-id-type="pmid">17262190</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Castro</surname><given-names>S</given-names></name><name><surname>Teboul</surname><given-names>JL</given-names></name><name><surname>Singer</surname><given-names>M</given-names></name><name><surname>Rocco</surname><given-names>M</given-names></name><name><surname>Conti</surname><given-names>G</given-names></name><name><surname>Luca</surname><given-names>L</given-names></name><name><surname>Angelantonio</surname><given-names>E</given-names></name><name><surname>Orecchioni</surname><given-names>A</given-names></name><name><surname>Pandian</surname><given-names>NG</given-names></name><name><surname>Pietropaoli</surname><given-names>P</given-names></name></person-group><article-title>Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression</article-title><source>Intensive Care Med</source><year>2005</year><volume>31</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1007/s00134-005-2619-z</pub-id><pub-id pub-id-type="pmid">15812624</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheiermann</surname><given-names>P</given-names></name><name><surname>Ahluwalia</surname><given-names>D</given-names></name><name><surname>Hoegl</surname><given-names>S</given-names></name><name><surname>Dolfen</surname><given-names>A</given-names></name><name><surname>Revermann</surname><given-names>M</given-names></name><name><surname>Zwissler</surname><given-names>B</given-names></name><name><surname>Muhl</surname><given-names>H</given-names></name><name><surname>Boost</surname><given-names>KA</given-names></name><name><surname>Hofstetter</surname><given-names>C</given-names></name></person-group><article-title>Effects of intravenous and inhaled levosimendan in severe rodent sepsis</article-title><source>Intensive Care Med</source><year>2009</year><volume>35</volume><fpage>1412</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1007/s00134-009-1481-9</pub-id><pub-id pub-id-type="pmid">19367398</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Ertmer</surname><given-names>C</given-names></name><name><surname>Pietropaoli</surname><given-names>P</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name></person-group><article-title>Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function?</article-title><source>Curr Drug Targets</source><year>2009</year><volume>10</volume><fpage>863</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.2174/138945009789108819</pub-id><pub-id pub-id-type="pmid">19799540</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landry</surname><given-names>DW</given-names></name><name><surname>Oliver</surname><given-names>JA</given-names></name></person-group><article-title>The ATP-sensitive K<sup>+</sup> channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog</article-title><source>J Clin Invest</source><year>1992</year><volume>89</volume><fpage>2071</fpage><lpage>2074</lpage><pub-id pub-id-type="doi">10.1172/JCI115820</pub-id><pub-id pub-id-type="pmid">1602014</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukunari</surname><given-names>A</given-names></name><name><surname>Miyai</surname><given-names>H</given-names></name><name><surname>Shinagawa</surname><given-names>K</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name></person-group><article-title>Y-26763 protects the canine heart from a stunning injury through opening of the KATP channels</article-title><source>Eur J Pharmacol</source><year>1997</year><volume>323</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(97)00035-6</pub-id><pub-id pub-id-type="pmid">9128839</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Pride</surname><given-names>HP</given-names></name><name><surname>Zipes</surname><given-names>DP</given-names></name></person-group><article-title>Glibenclamide enhances but pinacidil reduces attenuation in sympathetic responsiveness after acute coronary artery occlusion</article-title><source>Circ Res</source><year>1994</year><volume>75</volume><fpage>379</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">8033347</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kersten</surname><given-names>JR</given-names></name><name><surname>Montgomery</surname><given-names>MW</given-names></name><name><surname>Pagel</surname><given-names>PS</given-names></name><name><surname>Warltier</surname><given-names>DC</given-names></name></person-group><article-title>Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels</article-title><source>Anesth Analg</source><year>2000</year><volume>90</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1097/00000539-200001000-00003</pub-id><pub-id pub-id-type="pmid">10624967</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Gross</surname><given-names>GJ</given-names></name></person-group><article-title>Glibenclamide antagonizes adenosine A1 receptor-mediated cardioprotection in stunned canine myocardium</article-title><source>Circulation</source><year>1993</year><volume>88</volume><fpage>235</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">8319338</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Gross</surname><given-names>GJ</given-names></name></person-group><article-title>A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of KATP channels</article-title><source>Circulation</source><year>1994</year><volume>89</volume><fpage>1229</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">8124811</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Morelli</surname><given-names>A</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of potassium channels in critical illness</article-title><source>Curr Opin Anaesthesiol</source><year>2008</year><volume>21</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1097/ACO.0b013e3282f3ad74</pub-id><pub-id pub-id-type="pmid">18443475</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maybauer</surname><given-names>DM</given-names></name><name><surname>Salsbury</surname><given-names>JR</given-names></name><name><surname>Westphal</surname><given-names>M</given-names></name><name><surname>Maybauer</surname><given-names>MO</given-names></name><name><surname>Salzman</surname><given-names>AL</given-names></name><name><surname>Szab&#x000f3;</surname><given-names>C</given-names></name><name><surname>Westphal-Varghese</surname><given-names>BB</given-names></name><name><surname>Traber</surname><given-names>LD</given-names></name><name><surname>Traber</surname><given-names>DL</given-names></name></person-group><article-title>The ATP-sensitive potassium-channel inhibitor glibenclamide improves outcome in an ovine model of hemorrhagic shock</article-title><source>Shock</source><year>2004</year><volume>22</volume><fpage>387</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000140661.78744.f6</pub-id><pub-id pub-id-type="pmid">15377897</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musser</surname><given-names>JB</given-names></name><name><surname>Bentley</surname><given-names>TB</given-names></name><name><surname>Griffith</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Karaian</surname><given-names>JE</given-names></name><name><surname>Mongan</surname><given-names>PD</given-names></name></person-group><article-title>Hemorrhagic shock in swine: nitric oxide and potassium sensitive adenosine triphosphate channel activation</article-title><source>Anesthesiology</source><year>2004</year><volume>101</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1097/00000542-200408000-00021</pub-id><pub-id pub-id-type="pmid">15277923</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarte</surname><given-names>LA</given-names></name><name><surname>Picker</surname><given-names>O</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Fournell</surname><given-names>A</given-names></name><name><surname>Scheeren</surname><given-names>TW</given-names></name></person-group><article-title>Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs</article-title><source>Crit Care Med</source><year>2005</year><volume>33</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000150653.89451.6F</pub-id><pub-id pub-id-type="pmid">15644660</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boller</surname><given-names>M</given-names></name><name><surname>Moens</surname><given-names>Y</given-names></name><name><surname>K&#x000e4;stner</surname><given-names>SB</given-names></name><name><surname>Bettschart-Wolfensberger</surname><given-names>R</given-names></name></person-group><article-title>Closed system anaesthesia in dogs using liquid sevoflurane injection; evaluation of the square-root-of-time model and the influence of CO<sub>2</sub> absorbent</article-title><source>Vet Anaesth Analg</source><year>2005</year><volume>32</volume><fpage>168</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1111/j.1467-2995.2005.00193.x</pub-id><pub-id pub-id-type="pmid">15877663</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenthal</surname><given-names>SR</given-names></name><name><surname>Skoula</surname><given-names>CM</given-names></name><name><surname>Gordon</surname><given-names>BE</given-names></name></person-group><article-title>Relationship between inspiratory pressure and tidal volume in the anesthetized canine</article-title><source>Lab Anim Sci</source><year>1998</year><volume>48</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9517894</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzenelson</surname><given-names>R</given-names></name><name><surname>Perel</surname><given-names>A</given-names></name><name><surname>Berkenstadt</surname><given-names>H</given-names></name><name><surname>Preisman</surname><given-names>S</given-names></name><name><surname>Kogan</surname><given-names>S</given-names></name><name><surname>Sternik</surname><given-names>L</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name></person-group><article-title>Accuracy of transpulmonary thermodilution versus gravimetric measurement of extravascular lung water</article-title><source>Crit Care Med</source><year>2004</year><volume>32</volume><fpage>1550</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000130995.18334.8B</pub-id><pub-id pub-id-type="pmid">15241101</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Pinsky</surname><given-names>MR</given-names></name></person-group><article-title>Effect of tidal volume, sampling duration, and cardiac contractility on pulse pressure and stroke volume variation during positive-pressure ventilation</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>2858</fpage><lpage>2862</lpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e3181865aea</pub-id><pub-id pub-id-type="pmid">18766112</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartges</surname><given-names>I</given-names></name><name><surname>Schwarte</surname><given-names>LA</given-names></name><name><surname>Fournell</surname><given-names>A</given-names></name><name><surname>Scheeren</surname><given-names>TW</given-names></name><name><surname>Picker</surname><given-names>O</given-names></name></person-group><article-title>Hypercapnia induces a concentration-dependent increase in gastric mucosal oxygenation in dogs</article-title><source>Intensive Care Med</source><year>2008</year><volume>34</volume><fpage>1898</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1007/s00134-008-1183-8</pub-id><pub-id pub-id-type="pmid">18575840</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohzuki</surname><given-names>H</given-names></name><name><surname>Sakata</surname><given-names>S</given-names></name><name><surname>Misawa</surname><given-names>H</given-names></name><name><surname>Takaki</surname><given-names>M</given-names></name></person-group><article-title>O<sub>2</sub> delivery and the venous PO<sub>2</sub>&#x02013;O<sub>2</sub> uptake relationship in pump-perfused canine muscle</article-title><source>Exp Physiol</source><year>2002</year><volume>87</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1113/eph8702249</pub-id><pub-id pub-id-type="pmid">11805858</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>R</given-names></name><name><surname>Sato</surname><given-names>J</given-names></name><name><surname>Nishino</surname><given-names>T</given-names></name></person-group><article-title>Milrinone decreases both pulmonary arterial and venous resistances in the hypoxic dog</article-title><source>Br J Anaesth</source><year>1998</year><volume>81</volume><fpage>920</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">10211020</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>TJ</given-names></name><name><surname>Ficke</surname><given-names>DJ</given-names></name><name><surname>Arain</surname><given-names>SR</given-names></name><name><surname>Holtz</surname><given-names>MN</given-names></name><name><surname>Shankar</surname><given-names>H</given-names></name></person-group><article-title>Vasodilation from sufentanil in humans</article-title><source>Anesth Analg</source><year>2005</year><volume>101</volume><fpage>1677</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1213/01.ANE.0000184119.85400.0E</pub-id><pub-id pub-id-type="pmid">16301240</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knotzer</surname><given-names>H</given-names></name><name><surname>Maier</surname><given-names>S</given-names></name><name><surname>D&#x000fc;nser</surname><given-names>MW</given-names></name><name><surname>Hasibeder</surname><given-names>WR</given-names></name><name><surname>Hausdorfer</surname><given-names>H</given-names></name><name><surname>Brandner</surname><given-names>J</given-names></name><name><surname>Torgersen</surname><given-names>C</given-names></name><name><surname>Ulmer</surname><given-names>H</given-names></name><name><surname>Friesenecker</surname><given-names>B</given-names></name><name><surname>Iannetti</surname><given-names>C</given-names></name><name><surname>Pajk</surname><given-names>W</given-names></name></person-group><article-title>Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1007/s00134-005-2858-z</pub-id><pub-id pub-id-type="pmid">16328220</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakob</surname><given-names>SM</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name></person-group><article-title>ARDS. Monitoring tissue perfusion</article-title><source>Crit Care Clin</source><year>2002</year><volume>18</volume><fpage>143</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/S0749-0704(03)00070-8</pub-id><pub-id pub-id-type="pmid">11910727</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Severinghaus</surname><given-names>JW</given-names></name></person-group><article-title>Continuous positive airway pressure, shock therapy, and gastric mucosal oxygenation</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>1870</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000063280.30785.81</pub-id><pub-id pub-id-type="pmid">12794438</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adnot</surname><given-names>S</given-names></name><name><surname>Radermacher</surname><given-names>P</given-names></name><name><surname>Andrivet</surname><given-names>P</given-names></name><name><surname>Dubois-Rande</surname><given-names>JL</given-names></name><name><surname>Dupeyrat</surname><given-names>A</given-names></name><name><surname>Lemaire</surname><given-names>F</given-names></name></person-group><article-title>Effects of sodium-nitroprusside and urapidil on gas exchange and ventilation-perfusion relationships in patients with congestive heart failure</article-title><source>Eur Respir J</source><year>1991</year><volume>4</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">1673933</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mace</surname><given-names>SE</given-names></name></person-group><article-title>Effect of hypoxemia on pharmacokinetics of endotracheal lidocaine in dogs</article-title><source>Resuscitation</source><year>1990</year><volume>20</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/0300-9572(90)90085-S</pub-id><pub-id pub-id-type="pmid">2171117</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brezina</surname><given-names>A</given-names></name><name><surname>Riha</surname><given-names>H</given-names></name><name><surname>Pirk</surname><given-names>J</given-names></name></person-group><article-title>Prophylactic application of levosimendan in cardiac surgical patients with severe left ventricle dysfunction</article-title><source>Exp Clin Cardiol</source><year>2009</year><volume>14</volume><fpage>31</fpage><lpage>34</lpage></mixed-citation></ref></ref-list><fn-group><fn><p>This article is discussed in the editorial available at doi:10.1007/s00134-011-2204-6.</p></fn></fn-group></back></article>